Development of Antibody‐Directed Therapies: Quo Vadis?

Less is more: The efficacy of antibody–drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.[Image: see text]

Detalles Bibliográficos
Autores principales: Rodrigues, Tiago, Bernardes, Gonçalo J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Highlights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838556/
https://www.ncbi.nlm.nih.gov/pubmed/29341367
http://dx.doi.org/10.1002/anie.201712185
_version_ 1783304284630155264
author Rodrigues, Tiago
Bernardes, Gonçalo J. L.
author_facet Rodrigues, Tiago
Bernardes, Gonçalo J. L.
author_sort Rodrigues, Tiago
collection PubMed
description Less is more: The efficacy of antibody–drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.[Image: see text]
format Online
Article
Text
id pubmed-5838556
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58385562018-03-12 Development of Antibody‐Directed Therapies: Quo Vadis? Rodrigues, Tiago Bernardes, Gonçalo J. L. Angew Chem Int Ed Engl Highlights Less is more: The efficacy of antibody–drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.[Image: see text] John Wiley and Sons Inc. 2018-01-17 2018-02-19 /pmc/articles/PMC5838556/ /pubmed/29341367 http://dx.doi.org/10.1002/anie.201712185 Text en © 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Highlights
Rodrigues, Tiago
Bernardes, Gonçalo J. L.
Development of Antibody‐Directed Therapies: Quo Vadis?
title Development of Antibody‐Directed Therapies: Quo Vadis?
title_full Development of Antibody‐Directed Therapies: Quo Vadis?
title_fullStr Development of Antibody‐Directed Therapies: Quo Vadis?
title_full_unstemmed Development of Antibody‐Directed Therapies: Quo Vadis?
title_short Development of Antibody‐Directed Therapies: Quo Vadis?
title_sort development of antibody‐directed therapies: quo vadis?
topic Highlights
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838556/
https://www.ncbi.nlm.nih.gov/pubmed/29341367
http://dx.doi.org/10.1002/anie.201712185
work_keys_str_mv AT rodriguestiago developmentofantibodydirectedtherapiesquovadis
AT bernardesgoncalojl developmentofantibodydirectedtherapiesquovadis

Ejemplares similares